Plans for robot-assisted surgery will forever change procedures in N.L., surgeons say
Tools will allow for surgical precision not before seen in N.L., docs say
Image | Surgeon operating with robot system
Caption: The Health Care Foundation, a Newfoundland and Labrador non-profit, is more than halfway to its $8 million fundraising goal to introduce the da Vinci XI surgical robot system into operating rooms. (Saint John Regional Hospital Foundation)
Plans to introduce robot-assisted surgery tools to Newfoundland and Labrador's health-care system were unveiled to the public on Wednesday, and the Health Care Foundation says it's already over halfway toward its fundraising goal to make it a reality.
Health Care Foundation president and CEO Paul Snow said $4.8 million of a needed $8 million has already been raised since December. It would be used to bring the da Vinci Xi surgical robot system into operating rooms.
"Today marks the beginning of a very bold, new chapter in surgical care in Newfoundland and Labrador," Snow said Wednesday.
"Our ongoing collaboration with Newfoundland and Labrador Health Services, the government of Newfoundland and Labrador and the many generous individuals, organizations, groups, family and friends that are committed to advancing care is what makes this progress possible."
NLHS eastern zone COO Ron Johnson said the technology will change surgery in the province, allowing for minimally invasive surgery to be done in ways not possible before.
"It's going to give shorter recovery times for very, very invasive surgery — Something now that you would have to leave this province to get otherwise," Johnson said. "It's going to benefit us. It's going to be shorter lengths of stay, meaning more people will be able to get more surgeries."
Surgeons in the province are eager to get their hands on the tool, according to Dr. Angela Bussey. A training unit is currently at the Health Sciences Centre, and the hope is that the system can be integrated soon.
"We're going to be able to create a situation in the [operating room] where surgeons are comfortable doing life-saving, complex procedures. And we've not been able to do that in this way to date," Bussey said.
"Envision the deepest, darkest place that you could go, and put a grain of sand there or a little piece of corn. [Then] be like, 'Get that for me.' You could never do it with your hands. But with the da Vinci, you can do that. And think about that being a very small amount of cancer or other disease that someone needs to get rid of. And we're able to do that."
Bussey said it will also serve as a key training tool for surgeons, as the machine's multiple screens will allow surgeons to observe procedures while they are being performed by another surgeon.
She added it can also serve as a key recruitment and retention tool, as cutting-edge technology is brought to Newfoundland and Labrador.
Joannie Neveu, a gynecology oncologist, said it will be a game changer.
"We use the robot as a surgical equipment that is going to be, basically, the extension of what we can do," she said.
"There's also less complication, right? Less bleeding and better recovery. The patient can go back to work or back to their life quicker."
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Globe and Mail
08-05-2025
- Globe and Mail
With Competition Rising, Should Investors Give Up On This Top Growth Stock?
Intuitive Surgical (NASDAQ: ISRG) has delivered market-crushing returns over the past two decades, thanks to its leadership in the robotic-assisted surgery (RAS) market. Part of the company's appeal is that its crown jewel has had little competition. However, that may change soon. Recent developments suggest that Intuitive's famous RAS device, the da Vinci system, will finally go head-to-head in the U.S. with another robot device. This might suggest that Intuitive Surgical can no longer produce outsize returns, but there's more to the story. Where to invest $1,000 right now? Our analyst team just revealed what they believe are the 10 best stocks to buy right now. Learn More » Here's what investors need to know. Meet the Hugo system Other RAS gadgets are cleared for use in the U.S., but for the most part, they're approved for procedures that have no overlap with those the da Vinci system helps perform. Stryker markets a robot surgeon called Mako, which is approved for partial and total knee operations and hip surgeries. Zimmer Biomet 's Rosa Knee system competes with the Mako. The list of approved procedures for the da Vinci system does not include total knee replacement. It does include urologic and cardiac surgeries, bariatric surgeries, and more. Intuitive Surgical helps perform minimally invasive surgeries with its devices, yet it still has to compete with other devices that aid more invasive types of operations. But there's been little direct competition from robot systems across the range of its approved procedures. That might be changing soon. Medtronic (NYSE: MDT), a leading medical-device maker, recently announced it had submitted an application to the U.S. Food and Drug Administration (FDA) for its Hugo system for use in urologic procedures. That's after the device performed well in a clinical trial on 137 patients. The Hugo system has been in use for years in many other countries, but its grand entrance in the U.S. -- if it does earn clearance from the FDA -- could be a big deal for Medtronic. It will also mean stiffer competition for the da Vinci system, at least in urologic procedures. Could that spell the end of Intuitive Surgical's dominance and market-beating days? Still a great stock to buy There are several things to note about Intuitive's da Vinci system and the challenges coming from the Hugo system. First, the da Vinci is approved both for urologic procedures and many others. It's spent years being tested and earning regulatory clearances across a range of therapeutic areas. It will take time for any single robot system, or even several of them, to challenge the da Vinci system in most of these markets. Consider that the rise of weight loss drugs disrupted the company's volume in bariatric surgeries, but since these made up only 4% to 5% of its total procedures, its financial results were barely affected. Second, even with mounting competition, there's substantial white space in the RAS market. Medtronic saw this opportunity and decided to jump in; it pointed out two years ago that only 5% of procedures that could be performed robotically actually were. This number is unlikely to have increased substantially in the meantime. So even with Medtronic's entrance, Intuitive has a significant growth runway. Third, Intuitive Surgical benefits from a strong moat. Its devices cost between $700,000 and $2.5 million, a substantial investment for healthcare facilities. The company does make it easier by offering flexible payment options, making its products more affordable. But after spending that kind of money, its customers won't want to switch to competing devices -- a classic example of switching costs. Finally, there's far more clinical evidence for the better-established da Vinci system than there is for the newcomer Hugo, meaning physicians are still more likely to opt for the former when all other factors are equal. The Hugo should become successful in the long run, but that takes little away from Intuitive now. Intuitive Surgical should still deliver excellent financial results and stock-market performance, just as in the past. That's why I think it's a good idea to purchase the company's shares and hold on to them for a long time. Should you invest $1,000 in Intuitive Surgical right now? Before you buy stock in Intuitive Surgical, consider this: The Motley Fool Stock Advisor analyst team just identified what they believe are the 10 best stocks for investors to buy now… and Intuitive Surgical wasn't one of them. The 10 stocks that made the cut could produce monster returns in the coming years. Consider when Netflix made this list on December 17, 2004... if you invested $1,000 at the time of our recommendation, you'd have $613,546!* Or when Nvidia made this list on April 15, 2005... if you invested $1,000 at the time of our recommendation, you'd have $695,897!* Now, it's worth noting Stock Advisor 's total average return is893% — a market-crushing outperformance compared to162%for the S&P 500. Don't miss out on the latest top 10 list, available when you join Stock Advisor. See the 10 stocks » *Stock Advisor returns as of May 5, 2025 Prosper Junior Bakiny has positions in Intuitive Surgical. The Motley Fool has positions in and recommends Intuitive Surgical. The Motley Fool recommends Medtronic and recommends the following options: long January 2026 $75 calls on Medtronic and short January 2026 $85 calls on Medtronic. The Motley Fool has a disclosure policy.
CBC
01-05-2025
- CBC
Family's experience with genetic testing inspires winning project in medical innovation challenge
Alyson Cronkhite knew soon after giving birth that something was wrong with her son. Though he was born at a healthy weight, seven pounds 13 ounces, his weight soon dropped drastically. He also did not sit up, walk, or talk at expected times. As medical staff tested the little boy for a possible genetic disease, results ultimately had to be sent to Finland for diagnosis, because her home province of New Brunswick does not have the ability to do it. Now Cronkhite, a medical technologist, is part of a team that is working on possible solutions — and her experience helped inform a project that recently received some important funding support through a local innovation challenge. Her story helped inspire Dr. Doha Itani of Saint John to create a project called Establishing Genetic Service in N.B., which won the $500,000 David Elias CHS Health Care Innovation Award on April 24. Cronkhite said that the family was worried about her son immediately after he was born. Her son underwent extensive medical tests "right from the start" — such as MRIs, ECGs and EEGs — but these all came back normal. Nobody in New Brunswick could tell them what was causing the issues. After sending test results to Finland, Cronkhite learned that her son is one of just four people in the world with a disease that is so rare, it does not have a name and is referred to only as a "global developmental delay." Right now, the family has to travel out of province several times a year to meet a health-care provider. Itani said the focus is developing the ability to do tests for serious genetic or hereditary diseases at home. Doing this "will dramatically cut current wait times, leading to greater access to diagnostic testing and screening for preventative, life-saving care right here in New Brunswick," the leaders said in a statement. Itani said that all of the functional genes in someone's DNA are referred to as "whole exome." In a statement, she likened the project to "copying the entire book… but looking for misprints in only the chapter that is relevant." The overall goal of the project is to improve access to care in New Brunswick so that patients do not need to leave the province to receive it, Itani said. She also said that New Brunswick's population is now large enough to add the testing that people need. The Medical Innovators' Challenge was a Dragon's Den -style event organized by the Saint John Regional Hospital Foundation. Another project, titled Meet the Kids Where They Are, was awarded the $100,000 Community Impact Award. Meet the Kids Where They Are will "expand to add a school and health liaison role in three Saint John schools," Alex Davis, a consultant working with the hospital foundation, said. "This will help support children facing social and health challenges by providing timely health care, early interventions and community resources." According to the foundation's news release, the award "was created to celebrate solutions that extend health care access beyond hospital walls." Meet the Kids Where They Are is led by Dr. Sarah Gander, a social pediatrician.
Global News
28-04-2025
- Global News
Manitoba welcomes cutting-edge surgical robot
Manitoba's health care just got a high-tech upgrade with the debut of the province's first surgical robot, the da Vinci Xi, now operational at the Health Sciences Centre (HSC) in Winnipeg. The $3.5 million da Vinci Xi, funded through the HSC Foundation's Operation Excellence campaign, has already been used for about 135 surgical cases at the HSC so far. View image in full screen Surgeons control the robot from a console moving its wristed instruments — which bend and rotate beyond — while viewing the surgical site in a magnified image. HSC foundation 'Acquiring Manitoba's first surgical robot is a major milestone for patient care,' said Jonathon Lyon, president and CEO of HSC Foundation. 'With the robot, patients will experience less pain, less blood loss, and lower risks of complications.' Story continues below advertisement The machine is divided into three parts: the surgeon console, patient-side cart and the vision cart. Get breaking National news For news impacting Canada and around the world, sign up for breaking news alerts delivered directly to you when they happen. Sign up for breaking National newsletter Sign Up By providing your email address, you have read and agree to Global News' Terms and Conditions and Privacy Policy The surgeon sits in the console to control the robot's arms and surgical instruments. The side cart, which is next to the patient, holds the robot's arms, surgical equipment and the camera. And the vision cart helps support the 3D high-definition vision system, allowing the surgeon to get a clear picture of the operational zone. During the announcement, HSC shared the recovery journey of a 33-year-old construction worker who was diagnosed with lung cancer after coughing up blood in December. 'Because of the precision of the robot, we were able to completely remove his lung cancer by taking out a small section of a patient's lung,' said Dr. Gilly Akhtar-Danesh, a thoracic surgeon at the HSC. 'The patient was discharged the next morning' Akhtar-Danesh added that the patient was able to return to work in under two weeks. View image in full screen HSC says that with robotic surgery, they're seeing a reduction in surgical complications, better post-surgery patient recovery and decreased surgical wait times. The da Vinci Xi will be used for thoracic surgeries (lung and esophageal cancer procedures), gynecologic oncology cases and urologic surgeries.
